title: Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.
authors.affiliation: Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Ganghammer
authors.affiliation: Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
authors.forename: Julia
authors.initials: J
authors.lastname: Gutjahr
authors.affiliation: Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
authors.forename: Evelyn
authors.initials: E
authors.lastname: Hutterer
authors.affiliation: Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
authors.forename: Peter W
authors.initials: PW
authors.lastname: Krenn
authors.affiliation: Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
authors.forename: Susanne
authors.initials: S
authors.lastname: Pucher
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.
authors.forename: Claudia
authors.initials: C
authors.lastname: Zelle-Rieser
authors.affiliation: Tyrolean Cancer Research Institute, Innsbruck, Austria.
authors.forename: Karin
authors.initials: K
authors.lastname: Jöhrer
authors.affiliation: Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division Medicinal Chemistry, VU University Amsterdam, the Netherlands.
authors.forename: Maikel
authors.initials: M
authors.lastname: Wijtmans
authors.affiliation: Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division Medicinal Chemistry, VU University Amsterdam, the Netherlands.
authors.forename: Rob
authors.initials: R
authors.lastname: Leurs
authors.affiliation: Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division Medicinal Chemistry, VU University Amsterdam, the Netherlands.
authors.forename: Martine J
authors.initials: MJ
authors.lastname: Smit
authors.affiliation: Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, Aviano, Italy.
authors.forename: Valter
authors.initials: V
authors.lastname: Gattei
authors.affiliation: Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria.
authors.forename: Richard
authors.initials: R
authors.lastname: Greil
authors.affiliation: Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria Salzburg Cancer Research Institute, Austria t.hartmann@salk.at.
authors.forename: Tanja N
authors.initials: TN
authors.lastname: Hartmann
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D054357:Chemokine CXCL10 / Q000494:pharmacology; D054371:Chemokine CXCL11 / Q000494:pharmacology; D054370:Chemokine CXCL9 / Q000494:pharmacology; D002633:Chemotaxis / Q000187:drug effects; D018450:Disease Progression; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008213:Lymphocyte Activation / Q000187:drug effects; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011237:Predictive Value of Tests; D061251:Primary Cell Culture; D011379:Prognosis; D012372:ROC Curve; D020239:Receptor Cross-Talk / Q000276:immunology*; D054367:Receptors, CXCR3 / Q000235:genetics* / Q000276:immunology; D019718:Receptors, CXCR4 / Q000235:genetics* / Q000276:immunology; D015398:Signal Transduction; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: C586675:5-chloro-6-(4-(1-(4-chlorobenzyl)piperidin-4-yl)-3-ethylpiperazin-1-yl)-N-ethylnicotinamide; D000970:Antineoplastic Agents; C114753:CXCL10 protein, human; C515202:CXCL11 protein, human; C080810:CXCL9 protein, human; C515187:CXCR3 protein, human; C527276:CXCR4 protein, human; D054357:Chemokine CXCL10; D054371:Chemokine CXCL11; D054370:Chemokine CXCL9; D010879:Piperazines; D054367:Receptors, CXCR3; D019718:Receptors, CXCR4; D009536:Niacinamide
keywords: B-cell receptor; CLL; CXCL12; chemokine; microenvironment